Evolus, Inc.

Item 1.01 Entry into a Material Definitive Agreement. Symatese License Amendment - Addition of Australia, New Zealand and Canada On August 3, 2026, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”), and Symatese Aesthetics S.A.S. (“Symatese”) entered into an amendment (the “Amendment”) to the License, Supply and Distribution Agreement dated December 20, 2023 (the “Agreement”), which the Company previously disclosed in a Current Report on Form 8-K filed on December 20, 2023. The Amendment expands the territory covered by the Agreement to include (i) Canada and (ii) Australia and New Zealand combined, and grants Evolus Europe exclusive rights to commercialize and distribute the full line of Estyme® branded injectable hyaluronic acid gels in those territories. As consideration for the additional rights, Evolus Europe is required to pay €920,000 in upfront signing payments and up to an additional €1.38 million upon receipt of certain regulatory approvals. Symatese will be responsible, at its expense, for the development and regulatory activities required to obtain and maintain regulatory approvals in the additional territories. The initial term for each new territory is 15 years from the first applicable regulatory approval and will automatically renew for successive five-year terms, subject to the terms of the Agreement. The foregoing is a summary of the terms of the Amendment and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.

Item 7.01 Regulation FD Disclosure. On August 4, 2026, the Company issued a press release announcing the execution of the Amendment. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.